Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of PDS0101 in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection After Failure with Platinum-Based Chemotherapy

Trial Profile

A Phase 2 study of PDS0101 in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection After Failure with Platinum-Based Chemotherapy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2019 According to a PDS Biotechnology Corporation media release, company has completed manufacturing of clinical batches of PDS0101 with its partner BSP Pharmaceuticals S.p.A .The clinical batches of PDS0101 will be used in this study. Company is now working diligently to qualify clinical sites for this study
    • 19 Sep 2019 According to a PDS Biotechnology Corporation media release, this study is expected to start in the first quarter of 2020.
    • 18 Mar 2019 According to a PDS Biotechnology Corporation media release, this study is expected to start in the fourth quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top